Investor Relations

DBV Technologies is a global biopharmaceutical company focused on discovering, developing, manufacturing and commercializing treatments for severe allergies

News

DBV Technologies Announces ToplineResults of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age

Documentation

20F- Form 2016

Investor Relations

Phone : +33 1 55 42 78 78
Fax : +33 1 43 26 10 83

Subscribe to get the latest DBV’s News